A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2017
At a glance
- Drugs Irinotecan (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 03 Jan 2017 Status changed from active, no longer recruiting to completed.
- 09 Oct 2012 Planned end date changed from 1 Jun 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 09 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.